Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases, ...
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO ...
1d
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a ...
Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...
GlobalData on MSN16h
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseasesNanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.
in.investing.com on MSN2d
Novo Nordisk shares down on report of potential Ozempic price cutsA/S fell on Wednesday after Bloomberg reported that Ozempic, Novo Nordisk’s diabetes drug, is ”very likely” to be one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback